PhaseBio Pharmaceuticals appoints director

Workflow Solutions
Products
See more S&P Global Solutions
See More IHS Markit Solutions
Content
How We Can Help
See More
News & Insights Topics
See More
Featured Events
In PersonPolitics & Policy: Market Impacts and Mid-Year Outlooks
- 06/24/2022
- Sofitel Washington DC Lafayette Square
- 8:30 AM – 12:00 PM ET
Webinar ReplaysExpand Your Perspective: Unlocking Insights Across the Supply Chain
- 05/11/2022
- On-Demand
- 1 Hour
Conference10th Annual Community Bankers Conference
- 05/16/2022
- Four Seasons Resort and Club, Dallas at Las Colinas
- Dallas, Texas
Platforms
Other Products
- Leveraged Commentary and Data
- Research Online

In This List

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

18 Dec, 2018

Author Ayesha Hassan
Theme Healthcare & Pharmaceuticals

PhaseBio Pharmaceuticals Inc. appointed Edmund Harrigan to its board, effective Dec. 13.

Harrigan is also a board member of Bellicum Pharmaceuticals Inc., Karuna Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc. and Lyndra Therapeutics.

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat orphan diseases.